Successful treatment of donor‐derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens
- 22 February 2017
- journal article
- case report
- Published by Wiley in Transplant Infectious Disease
- Vol. 19 (2)
Abstract
We report here the successful treatment of hepatitis C virus (HCV) transmitted from a nucleic acid testing (NAT)‐negative donor to three HCV‐negative recipients—two renal transplants and one liver. Both renal recipients underwent standard deceased‐donor renal transplantation with immediate graft function. The liver recipient underwent standard orthotopic liver transplantation and recovered uneventfully. The donor was a 39‐year‐old woman with a terminal serum creatinine of 0.7 mg/dL. She was high risk for bloodborne pathogens, based upon a history of sexual contact with an HCV‐infected male partner. Recipient 1 was a 45‐year‐old man with a history of end‐stage renal disease from systemic lupus erythematosus. Recipient 2 was a 62‐year‐old woman with a history of end‐stage renal disease caused by hypertension and insulin‐dependent diabetes. Recipient 3 was a 42‐year‐old man with acute liver failure from acetaminophen ingestion. All recipients became HCV polymerase chain reaction positive on post‐transplant follow‐up. Both kidney recipients were treated with ledipasvir/sofosbuvir combination therapy for 12 weeks without side effects or rejection episodes. Recipient 3 was treated with ledipasvir/sofosbuvir in combination with ribavirin for 12 weeks without side effects. All patients achieved a sustained viral response at 12 weeks and are considered cured of HCV. The kidney recipients maintained good allograft function with a serum creatinine of 1.4 mg/dL and 1.0 mg/dL, respectively. Both renal recipients maintained normal liver function post treatment and did not develop any evidence of fibrosis. The liver recipient's liver function tests returned to normal without further incident. This case report provides evidence for the successful treatment of donor‐derived HCV in transplant recipients.Keywords
This publication has 18 references indexed in Scilit:
- An Interferon-free Antiviral Regimen for HCV after Liver TransplantationNew England Journal of Medicine, 2014
- Sexual transmission of hepatitis C virus among monogamous heterosexual couples: The HCV partners studyHepatology, 2012
- Risk of Window Period Hepatitis-C Infection in High Infectious Risk Donors: Systematic Review and Meta-AnalysisAmerican Journal of Transplantation, 2011
- Centers for Disease Control ‘High-Risk’ Donors and Kidney UtilizationAmerican Journal of Transplantation, 2010
- Transplantation of Kidneys from Donors at Increased Risk for Blood-Borne Viral Infection: Recipient Outcomes and Patterns of Organ UseAmerican Journal of Transplantation, 2009
- Peginterferon alfa‐2a for hepatitis C after liver transplantationHepatology, 2005
- Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPSKidney International, 2004
- Donor Hepatitis C SeropositivityJournal of the American Society of Nephrology, 2002
- Longitudinal Analysis of Hepatitis C Virus Replication and Liver Fibrosis Progression in Renal Transplant RecipientsThe Journal of Infectious Diseases, 2000
- Long-Term Outcome of Hepatitis C Infection after Liver TransplantationNew England Journal of Medicine, 1996